Table 1.
Selected off-the-shelf and point-of-care NK products in clinical development derived from PB, CB, or iPSCs from 490 NK cell clinical trials
| Sponsor | Therapy name | CAR | Target | Cell source | Disease | Clinical trial number | Clinical phase |
|---|---|---|---|---|---|---|---|
| Wuhan Union Hospital, China | — | + | CD19 | CB | B-cell malignancies | NCT04796675 | Phase 1 |
| Hangzhou Cheetah Cell Therapeutics Co, Ltd | — | + | NKG2D | CB | AML | NCT05247957 | Phase 1 |
| Xinqiao Hospital of Chongqing | — | + | BCMA | CB | MM | NCT05008536 | Phase 1 |
| Washington University | CIML NK cells | − | PBMC memory-like |
r/r AML after allo-HCT |
NCT03068819 | Phase 1/2∗ | |
| Washington University | CIML NK cells | − | PBMC memory-like |
AML with haplo-HCT | NCT02782546 | Phase 2∗ | |
| Wugen Inc | WU-NK-101 | − | PBMC memory-like, expanded | r/r AML | NCT05470140 | Phase 1 | |
| MDACC | CAR.70/IL5 | CD70 | CB | r/r hematologic malignancies | NCT05092451 | Phase 1/2 | |
| MDACC | AFM13-NK | − | CD30 | CB | HL, NHL | NCT04074746 | Phase 1/2 |
| MDACC | iC9/CAR.19/IL15 | + | CD19 | CB | r/r B-lymphoid malignancies | NCT03056339 | Phase 1/2 |
| Takeda | TAK-007 | + | CD19 | CB | r/r NHL | NCT05020015 | Phase 2 |
| CHLA | Haplo–IL-21 NK | − | — | PBMC IL-21 expanded |
AML with HCT |
NCT04836390 | Phase 2∗ |
| Ohio State | KDS-1001 | − | PBMC mIL-21 expanded | AML | NCT04220684 | Phase 1 | |
| Ohio State/NWC | UD-NK mIL-21 | PBMC mIL-21 UD expanded | r/r AML | NCT05503134 | Phase 1 | ||
| Ohio State | UD-NK mIL-21 | − | PBMC mIL-21 UD expanded |
CTLC | NCT04848064 | Phase 1 | |
| Kiadis/Sanofi | KDS-1001 | − | PBMC mIL-21 expanded | CML | NCT04808115 | Phase 1 | |
| Nkarta Inc | NKX101 | + | NKG2D | PBMC | AML, MDS | NCT04623944 | Phase 1 |
| Nkarta Inc | NKX019 | + | CD19 | PBMC | r/r NHL, CLL B-ALL |
NCT05020678 | Phase 1 |
| Nkarta Inc | NKX019 | + | CD19 | PBMC | r/r NHL, CLL B-ALL |
NCT05020678 | Phase 1 |
| Fate Therapeutics | FT576 | + | CD38 and BCMA | iPSC | r/r MM | NCT05182073 | Phase 1 |
| Fate Therapeutics | FT596 | + | CD19 | iPSC | NHL | NCT04245722 | Phase 1 |
| Fate Therapeutics | FT536 | − | CD38 mAb | iPSC | MM, solid tumors | NCT05395052 | Phase 1 |
| Fate Therapeutics | FT516 | − | CD20, B7-53, PD-L1 | iPSC | NHL, ovarian, RCC, Merkel cell | NCT04023071NCT04630769NCT04551885 | Phase 1 |
| Fate Therapeutics | FT500 | − | PD-1 | iPSC | NHL, solid tumors | NCT03841110 | Phase 1 |
Only clinical trials with available information on www.clinicaltrials.gov were considered.
ALL, acute lymphoblastic leukemia; allo, allogenic; BCMA, B-cell maturation antigen; CHLA, Children's Hospital Los Angeles; CIML, cytokine-induced memory-like; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CTLC, cutaneous T-cell lymphoma; HL, Hodgkin lymphoma; MDACC, MD Anderson Cancer Center; MDS, myelodysplastic syndrome; mIL-21, membrane-bound IL-21; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PBMC, peripheral blood mononuclear cells; RCC, renal cancer cell; UD, universal donor.
Point-of-care allogeneic product.